<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987294</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-346-202</org_study_id>
    <nct_id>NCT04987294</nct_id>
  </id_info>
  <brief_title>Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects With Gout and Mild to Moderate Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase IIa study is to evaluate the safety, tolerability and&#xD;
      pharmacodynamics of ALLN-346 in subjects with hyperuricemia and gout, and with mild to&#xD;
      moderate chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled parallel group, multi-center phase II&#xD;
      clinical study or orally administered ALLN-346 in subjects with hyperuricemia, gout and mild&#xD;
      to moderate chronic kidney disease over a two-week period. Subjects will be enrolled in two&#xD;
      cohorts based on estimated glomerular filtration rate (eGFR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 2:1 to receive ALLN-346 or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Subjects, Investigators and laboratories involved in the conduct of the study will be blinded to subject treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>42 days</time_frame>
    <description>Treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Urate</measure>
    <time_frame>14 Days</time_frame>
    <description>Serum urate [mg/dL]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>ALLN-346 (Engineered Urate Oxidase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-346 is novel urate oxidase provided as capsules for oral administration. ALLN-346 will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-346</intervention_name>
    <description>ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration</description>
    <arm_group_label>ALLN-346 (Engineered Urate Oxidase)</arm_group_label>
    <other_name>Engineered urate oxidase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 to 70 years&#xD;
&#xD;
          -  Serum UA level ≥ 8.0 mg/dL at Screening (hyperuricemia)&#xD;
&#xD;
          -  Meets 2015 American College of Rheumatology (ACR)/EULAR criteria for gout&#xD;
&#xD;
          -  Screening eGFR of ≥60 - &lt;90 mL/minute/1.73 m2 for Cohort A and ≥30 - &lt;60&#xD;
             mL/minute/1.73 m2 for Cohort B.&#xD;
&#xD;
          -  Concomitant medications stable for a minimum of 4 weeks prior to and during Screening&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18 and ≤ 40 kg/m2, inclusive, at screening&#xD;
&#xD;
          -  Not pregnant, not capable of pregnancy, not nursing, and agrees to use an effective&#xD;
             method of contraception; males subjects must agree to abstain from sperm donation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking any oral urate-lowering medication within 2 weeks prior to Screening&#xD;
&#xD;
          -  Prior uricase therapy or exposure to recombinant uricase, such as Rasburicase or&#xD;
             Pegloticase&#xD;
&#xD;
          -  Gout flare requiring treatment within 14 days prior to or during Screening&#xD;
&#xD;
          -  Clinically significant finding during Screening, any ongoing clinically significant&#xD;
             illness requiring a clinically significant intervention or change in management within&#xD;
             4 weeks prior to or during Screening&#xD;
&#xD;
          -  History of GI surgery, including gastric sleeve, Roux-en-Y or gastric banding (unless&#xD;
             gastric band removed for a minimum of 12 months prior to Screening&#xD;
&#xD;
          -  Received treatment with or exposure to an Investigational drug or device within 30&#xD;
             days - prior to or during Screening&#xD;
&#xD;
          -  Prior dosing in ALLN-346 clinical study&#xD;
&#xD;
          -  Per Investigator judgment, is not an ideal clinical study candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Tosone, MS, RAC</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>B Kandinov, PhD</last_name>
    <phone>(617) 467-4577</phone>
    <email>Clinical346@allenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Clark, RN</last_name>
      <phone>205-934-1444</phone>
      <email>sbiggers@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SYED Research Consultants, LLC</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loren McCoy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SYED Research Consultants, LLC</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Karr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orthopedic Physicians Alaska</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Botson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allameh Medical Facility</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Azadegan</last_name>
      <email>Research@DrAllameh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Martinez</last_name>
      <email>easternresearch.am@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Best Quality Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolfo Gutierrez-Alsina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Generation of Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karelia Ruiz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Chiong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Research, LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Barlow, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NY Total Medical Care, PC</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Serje, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Burke Primary Care</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Smith, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Summit research Group, LLC</name>
      <address>
        <city>Stow</city>
        <state>Ohio</state>
        <zip>44224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Rigby, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center, LLC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Kopyt, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>P&amp;I Clinical Research, LLC</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vickie Jones, LVN/CRN</last_name>
      <phone>936-465-9533</phone>
      <email>vjones@piclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Briggs Clinical Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Gaona, Sr., MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

